[{"orgOrder":0,"company":"Dexa Medica","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDONESIA","productType":"Hormone","year":"2021","type":"Collaboration","leadProduct":"Triptorelin Pamoate","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Powder for Injection","sponsorNew":"Dexa Medica \/ Debiopharm","highestDevelopmentStatusID":"15","companyTruncated":"Dexa Medica \/ Debiopharm"},{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH AFRICA","productType":"Hormone","year":"2022","type":"Partnership","leadProduct":"Triptorelin Pamoate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aspen Pharmacare Holdings","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aspen Pharmacare Holdings \/ Debiopharm","highestDevelopmentStatusID":"15","companyTruncated":"Aspen Pharmacare Holdings \/ Debiopharm"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Knight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Hormone","year":"2020","type":"Partnership","leadProduct":"Triptorelin Pamoate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Debiopharm \/ Knight Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Debiopharm \/ Knight Therapeutics"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Verity Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Hormone","year":"2020","type":"Agreement","leadProduct":"Triptorelin Pamoate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Debiopharm \/ Verity Pharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"Debiopharm \/ Verity Pharmaceuticals Inc"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"GnRH receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Financing","leadProduct":"Triptorelin Pamoate","moa":"GnRH receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foresee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Foresee Pharmaceuticals \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Triptorelin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Debiopharm to enter into this new alliance with Aspen, a well-established and trusted pharmaceutical partner for the commercialization of Trelstar® in South Africa and recognize the therapeutic benefits that Trelstar® could bring to prostate cancer pat...

                          Product Name : Trelstar

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          January 02, 2022

                          Lead Product(s) : Triptorelin Pamoate

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Debiopharm

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          Aspen API Comapny Banner

                          02

                          Plastics Recycling EU
                          Not Confirmed
                          Plastics Recycling EU
                          Not Confirmed

                          Details : Debio 4326 is a unique injectable, biodegradable 12-month extended-release formulation of triptorelin, being developed for pediatric participants for central precocious puberty.

                          Product Name : Trelstar

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          September 09, 2024

                          Lead Product(s) : Triptorelin Pamoate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Plastics Recycling EU
                          Not Confirmed
                          Plastics Recycling EU
                          Not Confirmed

                          Details : The net proceeds will be allocated to advancing the company’s pipeline, including FP-014 (triptorelin), a ready-to-use, long-acting injectable developed for the treatment of prostate cancer.

                          Product Name : FP-014

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          April 12, 2024

                          Lead Product(s) : Triptorelin Pamoate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : $42.1 million

                          Deal Type : Financing

                          blank

                          04

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Dexa Medica’s nation-wide launch and distribution of triptorelin, as Debiopharm’s exclusive Indonesian licensee, will help patients in the region gain access to the pain-relieving benefits of hormone suppression with Pamorelin®.

                          Product Name : Pamorelin

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          July 10, 2021

                          Lead Product(s) : Triptorelin Pamoate

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Sponsor : Debiopharm

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          Plastics Recycling EU
                          Not Confirmed
                          Plastics Recycling EU
                          Not Confirmed

                          Details : The companies have entered into an exclusive agreement that grants Verity Pharmaceuticals Inc. the rights to commercialize Trelstar® (triptorelin pamoate for injectable suspension), a hormone therapy for patients living with prostate cancer.

                          Product Name : Trelstar

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          September 06, 2020

                          Lead Product(s) : Triptorelin Pamoate

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Verity Pharmaceuticals Inc

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          06

                          Plastics Recycling EU
                          Not Confirmed
                          Plastics Recycling EU
                          Not Confirmed

                          Details : The agreement grants Knight the rights to commercialize Trelstar® (triptorelin) in Canada.

                          Product Name : Trelstar

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          August 01, 2020

                          Lead Product(s) : Triptorelin Pamoate

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Knight Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank